がん治療薬とバイオ治療薬の世界市場

がん治療薬とバイオ治療薬の世界市場は2030年までに2,765億米ドルに達する見込み

2024年に1,883億米ドルと推定されるがん治療薬とバイオ治療薬の世界市場は、2024年から2030年にかけてCAGR 6.6%で成長し、2030年には2,765億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである血液がんは、CAGR 5.6%を記録し、分析期間終了時には640億米ドルに達すると予測されます。中皮腫セグメントの成長率は、分析期間でCAGR 8.4%と推定されます。

米国市場は513億米ドルと推定、中国はCAGR 10.2％で成長予測

米国のがん治療薬とバイオ治療薬市場は2024年に513億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに565億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.4%と6.4%と予測されています。欧州では、ドイツがCAGR 4.3%で成長すると予測されています。

世界のがん治療薬とバイオ治療薬市場- 主要動向と促進要因のまとめ

なぜがん治療薬とバイオ治療薬はプレシジョン・オンコロジー、免疫療法、マルチメカニズム治療パラダイムにおいて戦略的重要性を増しているのか？

がん治療薬とバイオ治療薬は、治療戦略が広範な細胞毒性アプローチから高度に標的化されたメカニズム主導の介入へと進化するにつれ、パラダイムシフトが進行しています。この市場は、低分子化合物、モノクローナル抗体、チェックポイント阻害剤、抗体薬物複合体（ADC）、二重特異性抗体、細胞・遺伝子治療など、拡大する治療法のスペクトラムにまたがっており、それぞれが標的外毒性を最小限に抑えながらがん増殖を阻害するように調整されています。世界のがん罹患率の上昇と腫瘍の不均一性が従来の治療効果に課題する中、分子標的、免疫調節、ゲノム・プロファイリングを統合した治療薬の推進は戦略的必須事項となっています。

メラノーマ、肺がん、血液がん、膀胱がんなど、生存予後を一変させる免疫療法を筆頭に、生物学的治療薬はがん治療においてますます中心的な役割を果たすようになっています。従来の治療法とは異なり、生物学的治療薬は身体の免疫系を活性化したり、がん特有の経路をブロックすることで、特定の集団において長期的な寛解の可能性を提供します。次世代シークエンシング（NGS）、バイオマーカー診断、コンパニオン療法と相まって、がん生物治療薬は、適切な治療を適切な患者に適切なタイミングで提供することを目的としたプレシジョン・メディシン・イニシアチブに合致しつつあります。

モダリティ、プラットフォーム技術、併用戦略はどのように開発を進めているのか？

がん治療における継続的な技術革新は、洗練されたプラットフォーム技術と相乗的なモダリティの組み合わせによって推進されています。モノクローナル抗体や免疫チェックポイント阻害剤（PD-1、CTLA-4など）は、特異性を高め免疫原性を低下させるために、糖鎖工学やヒト化によって最適化されています。二重特異性抗体とADCは、マルチターゲット・エンゲージメントと腫瘍選択的細胞毒性を可能にしています。一方、CAR-T細胞療法、TCR改変T細胞、腫瘍浸潤リンパ球（TIL）療法は、自家および同種細胞治療のフロンティアを押し広げています。

プレシジョン・オンコロジーは、遺伝的に定義されたがんにおいて、RNAベースの治療薬、標的キナーゼ阻害剤、PARP阻害剤によって進歩しています。リキッドバイオプシーの統合、リアルタイムの腫瘍変異負荷解析、予測バイオマーカーの枠組みは、患者の層別化と治療の個別化をサポートしています。免疫療法と標的治療薬、化学療法、放射線療法を組み合わせた併用療法は、耐性メカニズムを克服し、奏効の持続性を高めるためにデザインされた、多角的ながん制御の基礎となりつつあります。

がん治療薬とバイオ治療薬の成長を牽引する適応症、地域パイプライン、商業戦略は？

白血病、リンパ腫、多発性骨髄腫などの血液悪性腫瘍と並んで、肺がん、乳がん、大腸がん、前立腺がんなどの固形がんが治療の中心となっています。膠芽腫、膵臓がん、トリプルネガティブ乳がん（TNBC）などの希少がんや治療困難がんは、高いアンメットニーズとバイオマーカー主導の治療機会により、パイプラインの関心が高まっています。

北米は、臨床技術革新、規制当局の承認、償還の面でリードしており、米国はがんバイオテクノロジーと免疫療法開発の中心地です。欧州は、EMAの一元的な承認パスウェイと、腫瘍学に特化した国の医療制度の下で、強力な導入でこれに続いています。アジア太平洋、特に中国は、現地のバイオファーマの技術革新、規制改革、迅速ながん治療薬の承認を通じて、開発と商業化の重要なハブとして加速しています。

市場戦略には、研究開発リスクを軽減し治療範囲を拡大するためのライセンシング契約、産学連携、マルチアセット・アライアンスなどが含まれます。CDMOとの提携は、バイオ治療薬の製造規模を拡大する上で極めて重要であり、一方、リアルワールドエビデンス（RWE）の創出とバリューベースの価格設定モデルは、市場参入と支払者の関与に影響を及ぼしています。コンパニオン診断薬、デジタル治療薬の統合、患者支援インフラは、アドヒアランスの向上と転帰の最適化のためにバンドルされています。

がん治療薬とバイオ治療薬市場の成長を促進する要因は何か？

がん治療薬とバイオ治療薬市場は、利害関係者がプレシジョン・メディシン、免疫腫瘍学、患者固有の治療パラダイムを軸に連携することで拡大しています。バイオファーマのパイプラインは、がんのステージを問わず、生存期間の延長だけでなくQOLの向上ももたらす疾患修飾療法を提供することにますます重点を置くようになっています。

主な成長要因としては、世界のがん罹患率の上昇、免疫に基づく治療の受け入れ拡大、標的同定とゲノム・プロファイリングの進歩、早期承認に向けた規制の柔軟性向上、がん研究開発への旺盛な投資などが挙げられます。併用レジメンの使用拡大、汎腫瘍適応、世界な臨床試験ネットワークは、市場の勢いをさらに強めています。

がん治療がバイオマーカー主導型、多剤併用型、根治を目指す戦略へと移行する中、治療薬と生物学的製剤が融合し、世界中で真に個別化され、耐久性があり、利用しやすいがん治療の次の時代が到来する可能性はあるのだろうか。

セグメント

がん種（血液がん、肺がん、大腸がん、前立腺がん、乳がん、子宮頸がん、頭頸部がん、膠芽腫、悪性髄膜腫、中皮腫、黒色腫、その他のがん種）、治療法（化学療法、標的療法、免疫療法、放射線療法、ホルモン療法、生物学的療法、その他の治療法）、エンドユーザー（病院・クリニック、がん治療センター、研究機関、その他のエンドユーザー）

調査対象企業の例（注目の44社）

• AbbVie Inc.
• Akeso, Inc.
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• BeiGene, Ltd.
• BioNTech SE
• Boehringer Ingelheim GmbH
• Bristol Myers Squibb
• Eli Lilly and Company
• Genentech, Inc.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Grifols, S.A.
• Johnson & Johnson
• Merck & Co., Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Roche Holding AG

AIインテグレーション

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Cancer Therapeutics and Biotherapeutics Market to Reach US$276.5 Billion by 2030

The global market for Cancer Therapeutics and Biotherapeutics estimated at US$188.3 Billion in the year 2024, is expected to reach US$276.5 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2024-2030. Blood Cancer, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$64.0 Billion by the end of the analysis period. Growth in the Mesothelioma segment is estimated at 8.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$51.3 Billion While China is Forecast to Grow at 10.2% CAGR

The Cancer Therapeutics and Biotherapeutics market in the U.S. is estimated at US$51.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$56.5 Billion by the year 2030 trailing a CAGR of 10.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Cancer Therapeutics and Biotherapeutics Market - Key Trends & Drivers Summarized

Why Are Cancer Therapeutics and Biotherapeutics Gaining Strategic Importance Across Precision Oncology, Immunotherapy, and Multi-Mechanism Treatment Paradigms?

Cancer therapeutics and biotherapeutics are undergoing a paradigm shift as treatment strategies evolve from broadly cytotoxic approaches to highly targeted, mechanism-driven interventions. This market spans an expanding spectrum of modalities-including small molecules, monoclonal antibodies, checkpoint inhibitors, antibody-drug conjugates (ADCs), bispecific antibodies, and cell and gene therapies-each tailored to disrupt cancer proliferation while minimizing off-target toxicity. As global cancer incidence rises and tumor heterogeneity challenges conventional treatment efficacy, the push for therapeutics that integrate molecular targeting, immune modulation, and genomic profiling has become a strategic imperative.

Biotherapeutics are playing an increasingly central role in oncology, with immunotherapies leading the charge in transforming survival outcomes across melanoma, lung, hematologic, and bladder cancers. Unlike traditional therapies, biotherapeutics activate the body’s immune system or block cancer-specific pathways, offering long-term remission potential in select populations. Coupled with next-generation sequencing (NGS), biomarker diagnostics, and companion therapies, cancer biotherapeutics are aligning with precision medicine initiatives aimed at delivering the right therapy to the right patient at the right time.

How Are Modalities, Platform Technologies, and Combination Strategies Advancing Cancer Therapeutics and Biotherapeutics Development?

Ongoing innovation in cancer treatment is being driven by sophisticated platform technologies and synergistic modality combinations. Monoclonal antibodies and immune checkpoint inhibitors (e.g., PD-1, CTLA-4) are being optimized through glycoengineering and humanization to enhance specificity and reduce immunogenicity. Bispecific antibodies and ADCs are enabling multi-target engagement and tumor-selective cytotoxicity. Meanwhile, CAR-T cell therapies, TCR-engineered T-cells, and tumor-infiltrating lymphocyte (TIL) therapies are pushing the frontier of autologous and allogeneic cellular treatments.

Precision oncology is being advanced through RNA-based therapeutics, targeted kinase inhibitors, and PARP inhibitors in genetically defined cancers. Liquid biopsy integration, real-time tumor mutational burden analysis, and predictive biomarker frameworks are supporting patient stratification and treatment personalization. Combination therapies-pairing immunotherapies with targeted drugs, chemotherapy, or radiotherapy-are becoming the cornerstone of multidimensional cancer control, designed to overcome resistance mechanisms and enhance response durability.

Which Indications, Regional Pipelines, and Commercial Strategies Are Driving Growth in Cancer Therapeutics and Biotherapeutics?

Solid tumors such as lung, breast, colorectal, and prostate cancer dominate treatment focus, alongside hematologic malignancies including leukemia, lymphoma, and multiple myeloma. Rare and difficult-to-treat cancers, including glioblastoma, pancreatic, and triple-negative breast cancer (TNBC), are attracting intensified pipeline interest due to high unmet need and biomarker-driven therapy opportunity.

North America leads in clinical innovation, regulatory approvals, and reimbursement adoption, with the U.S. at the epicenter of oncology biotech and immunotherapy development. Europe follows with strong adoption under centralized EMA approval pathways and oncology-focused national health systems. Asia-Pacific, particularly China, is accelerating as a key development and commercialization hub through local biopharma innovation, regulatory reforms, and fast-track oncology drug approvals.

Market strategies include licensing deals, academic-industry collaborations, and multi-asset alliances to mitigate R&D risk and expand therapeutic reach. CDMO partnerships are crucial for scaling biotherapeutics manufacturing, while real-world evidence (RWE) generation and value-based pricing models are influencing market access and payer engagement. Companion diagnostics, digital therapeutics integration, and patient-support infrastructure are being bundled to enhance adherence and optimize outcomes.

What Are the Factors Driving Growth in the Cancer Therapeutics and Biotherapeutics Market?

The cancer therapeutics and biotherapeutics market is expanding as stakeholders align around precision medicine, immuno-oncology, and patient-specific treatment paradigms. Biopharma pipelines are increasingly focused on delivering disease-modifying therapies that offer not only survival extension but also quality-of-life enhancement across cancer stages.

Key growth drivers include rising global cancer prevalence, growing acceptance of immune-based treatments, advances in target identification and genomic profiling, increasing regulatory flexibility for accelerated approvals, and strong investment in oncology R&D. Expanding use of combination regimens, pan-tumor indications, and global clinical trial networks further reinforce market momentum.

As cancer care transitions toward biomarker-driven, multi-modal, and curative-intent strategies, could therapeutics and biotherapeutics converge to define the next era of truly personalized, durable, and accessible oncology treatment worldwide?

SCOPE OF STUDY:

The report analyzes the Cancer Therapeutics and Biotherapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Cancer Type (Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma, Malignant Meningioma, Mesothelioma, Melanoma, Other Cancer Types); Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy, Other Therapies); End-User (Hospitals & Clinics, Cancer Care Centers, Research Institutes, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AbbVie Inc.
• Akeso, Inc.
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• BeiGene, Ltd.
• BioNTech SE
• Boehringer Ingelheim GmbH
• Bristol Myers Squibb
• Eli Lilly and Company
• Genentech, Inc.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Grifols, S.A.
• Johnson & Johnson
• Merck & Co., Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Roche Holding AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Cancer Therapeutics and Biotherapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Cancer Burden Throws the Spotlight on Targeted Therapeutic Innovation
  • Growth in Immunotherapy, Checkpoint Inhibitors, and Cell Therapy Drives Biotherapeutic Pipeline Expansion
  • Adoption of mRNA, Oncolytic Virus, and Gene-Editing Platforms Expands Mechanistic Diversity in Oncology
  • Expansion of Tumor-Agnostic Approvals and Basket Trials Accelerates Market Entry for Precision Therapies
  • Use of Companion Diagnostics and Genomic Profiling Supports Personalized Treatment Planning
  • Rising Investment in Biosimilars and Next-Gen Biologics Broadens Access and Cost Competitiveness
  • Growth in Orphan Oncology and Pediatric Cancer Research Supports Portfolio Diversification
  • Increased Global Access Through Patient Assistance Programs and Tiered Pricing Strengthens Uptake
  • Focus on Immune-Related Adverse Event Management and QoL Metrics Enhances Therapy Continuity
  • Adoption of AI and Multi-Omics Tools Accelerates Discovery of Novel Cancer Targets and Resistance Pathways
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Cancer Therapeutics and Biotherapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Cancer Therapeutics and Biotherapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Mesothelioma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Mesothelioma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Mesothelioma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Cervical Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Cervical Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Cervical Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Head & Neck Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Head & Neck Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Head & Neck Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Giloblastoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Giloblastoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Giloblastoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Malignant Meningioma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Malignant Meningioma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Malignant Meningioma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Hormone Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Biotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Biotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: World 15-Year Perspective for Biotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 59: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 60: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: World 15-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 62: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 63: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 65: World Recent Past, Current & Future Analysis for Cancer Care Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 66: World Historic Review for Cancer Care Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: World 15-Year Perspective for Cancer Care Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 68: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 69: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: World 15-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 71: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 72: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Cancer Therapeutics and Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 74: USA Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: USA Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: USA 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 77: USA Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: USA Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: USA 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 80: USA Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: USA Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: USA 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 83: Canada Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Canada Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Canada 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 86: Canada Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Canada Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Canada 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 89: Canada Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Canada Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Canada 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• JAPAN
  • Cancer Therapeutics and Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 92: Japan Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Japan Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Japan 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 95: Japan Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Japan Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Japan 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 98: Japan Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Japan Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Japan 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• CHINA
  • Cancer Therapeutics and Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 101: China Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: China Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: China 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 104: China Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: China Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: China 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 107: China Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: China Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: China 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• EUROPE
  • Cancer Therapeutics and Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Cancer Therapeutics and Biotherapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Europe 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Europe Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Europe 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 119: Europe Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Europe Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Europe 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• FRANCE
  • Cancer Therapeutics and Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 122: France Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: France 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: France 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 128: France Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: France Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: France 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• GERMANY
  • Cancer Therapeutics and Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Germany 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Germany 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Germany 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Italy 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Italy 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Italy 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Cancer Therapeutics and Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 149: UK Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: UK 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: UK 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Spain 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Europe Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Europe 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Cancer Therapeutics and Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 186: Asia-Pacific Historic Review for Cancer Therapeutics and Biotherapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Asia-Pacific 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Cancer Therapeutics and Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 197: Australia Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Australia Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Australia 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 200: Australia Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Australia Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Australia 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 203: Australia Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Australia Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Australia 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• INDIA
  • Cancer Therapeutics and Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 206: India Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: India Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: India 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 209: India Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: India Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: India 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 212: India Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: India Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: India 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 215: South Korea Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: South Korea Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: South Korea 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 218: South Korea Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: South Korea Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: South Korea 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 221: South Korea Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: South Korea Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: South Korea 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 224: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Rest of Asia-Pacific Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Rest of Asia-Pacific 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 227: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Asia-Pacific Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Asia-Pacific 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Asia-Pacific Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Asia-Pacific 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Cancer Therapeutics and Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 233: Latin America Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 234: Latin America Historic Review for Cancer Therapeutics and Biotherapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Latin America 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 236: Latin America Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Latin America Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Latin America 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 239: Latin America Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Latin America Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Latin America 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 242: Latin America Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Latin America Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Latin America 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 245: Argentina Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Argentina Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Argentina 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 248: Argentina Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Argentina Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Argentina 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 251: Argentina Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Argentina Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Argentina 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 254: Brazil Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Brazil Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Brazil 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 257: Brazil Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Brazil Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Brazil 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 260: Brazil Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Brazil Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Brazil 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 263: Mexico Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Mexico Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Mexico 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 266: Mexico Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Mexico Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Mexico 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 269: Mexico Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Mexico Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Mexico 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 272: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Rest of Latin America Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Rest of Latin America 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 275: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Rest of Latin America Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Rest of Latin America 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 278: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Rest of Latin America Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Rest of Latin America 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Cancer Therapeutics and Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 281: Middle East Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 282: Middle East Historic Review for Cancer Therapeutics and Biotherapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Middle East 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 284: Middle East Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Middle East Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Middle East 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 287: Middle East Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Middle East Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Middle East 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 290: Middle East Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Middle East Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Middle East 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 293: Iran Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Iran Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Iran 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 296: Iran Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Iran Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Iran 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 299: Iran Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Iran Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Iran 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 302: Israel Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Israel Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Israel 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 305: Israel Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Israel Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Israel 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 308: Israel Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Israel Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Israel 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 311: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Saudi Arabia Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Saudi Arabia 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 314: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Saudi Arabia Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Saudi Arabia 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 317: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Saudi Arabia Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Saudi Arabia 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 320: UAE Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: UAE Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: UAE 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 323: UAE Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: UAE Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: UAE 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 326: UAE Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: UAE Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: UAE 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 329: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Rest of Middle East Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Rest of Middle East 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 332: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Rest of Middle East Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Rest of Middle East 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 335: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Rest of Middle East Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Rest of Middle East 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030
• AFRICA
  • Cancer Therapeutics and Biotherapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 338: Africa Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Africa Historic Review for Cancer Therapeutics and Biotherapeutics by Cancer Type - Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Africa 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Mesothelioma, Melanoma, Other Cancer Types, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Giloblastoma and Malignant Meningioma for the Years 2015, 2025 & 2030
  • TABLE 341: Africa Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Africa Historic Review for Cancer Therapeutics and Biotherapeutics by Therapy - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Africa 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by Therapy - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Hormone Therapy, Biotherapy and Other Therapies for the Years 2015, 2025 & 2030
  • TABLE 344: Africa Recent Past, Current & Future Analysis for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Africa Historic Review for Cancer Therapeutics and Biotherapeutics by End-user - Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Africa 15-Year Perspective for Cancer Therapeutics and Biotherapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals & Clinics, Cancer Care Centers, Research Institutes and Other End-Users for the Years 2015, 2025 & 2030

IV. COMPETITION